Wolfson Julie, Sun Can-Lan, Wyatt Laura, Stock Wendy, Bhatia Smita
Institute for Cancer Outcomes and Survivorship, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Department of Population Sciences, City of Hope, Duarte, California.
Cancer Epidemiol Biomarkers Prev. 2017 Mar;26(3):312-320. doi: 10.1158/1055-9965.EPI-16-0722. Epub 2017 Feb 16.
Adolescents and young adults (AYA; 15-39 years) with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) experience inferior survival when compared with children. Impact of care at NCI-designated Comprehensive Cancer Centers (CCC) or Children's Oncology Group sites (COG) on survival disparities remains unstudied. Using the Los Angeles cancer registry, we identified 1,870 ALL or AML patients between 1 and 39 years at diagnosis. Cox regression analyses assessed risk of mortality; younger age + CCC/COG served as the referent group. Logistic regression was used to determine odds of care at CCC/COG, adjusting for variables above. ALL outcome: AYAs at non-CCC/COG experienced inferior survival (15-21 years: HR = 1.9, = 0.005; 22-29 years: HR = 2.6, < 0.001; 30-39 years: HR = 3.0, < 0.001). Outcome at CCC/COG was comparable between children and young AYAs (15-21 years: HR = 1.3, = 0.3; 22-29 years: HR = 1.2, = 0.2) but was inferior for 30- to 39-year-olds (HR = 3.4, < 0.001). AML outcome: AYAs at non-CCC/COG experienced inferior outcome (15-21 years: HR = 1.8, = 0.02; 22-39 years: HR = 1.4, = 0.06). Outcome at CCC/COG was comparable between children and 15- to 21-year-olds (HR = 1.3, = 0.4) but was inferior for 22- to 39-year-olds (HR = 1.7, = 0.05). Access: 15- to 21-year-olds were less likely to use CCC/COG than children ( < 0.001). In 22- to 39-year-olds, public/uninsured (ALL: = 0.004; AML<0.001), African American/Hispanics (ALL: = 0.03), and 30- to 39-year-olds (ALL: = 0.03) were less likely to use CCC/COG. Poor survival in AYAs with ALL and AML is mitigated by care at CCC/COG. Barriers to CCC/COG care include public/uninsured, and African American/Hispanic race/ethnicity. Care at CCC/COG explains, in part, inferior outcomes in AYAs with ALL and AML. Key sociodemographic factors serve as barriers to care at specialized centers. .
与儿童相比,患有急性淋巴细胞白血病(ALL)和急性髓细胞白血病(AML)的青少年及青年(AYA;15 - 39岁)生存率较低。国立癌症研究所指定的综合癌症中心(CCC)或儿童肿瘤学组机构(COG)的治疗对生存差异的影响尚未得到研究。利用洛杉矶癌症登记处的数据,我们确定了1870例诊断时年龄在1至39岁之间的ALL或AML患者。Cox回归分析评估死亡风险;年龄较小 + CCC/COG作为参照组。逻辑回归用于确定在CCC/COG接受治疗的几率,并对上述变量进行调整。ALL结果:非CCC/COG机构的AYA生存率较低(15 - 21岁:HR = 1.9,P = 0.005;22 - 29岁:HR = 2.6,P < 0.001;30 - 39岁:HR = 3.0,P < 0.001)。CCC/COG机构中儿童和年轻AYA(15 - 21岁)的结果相当(HR = 1.3,P = 0.3;22 - 29岁:HR = 1.2,P = 0.2),但30至39岁的患者结果较差(HR = 3.4,P < 0.001)。AML结果:非CCC/COG机构的AYA结果较差(15 - 21岁:HR = 1.8,P = 0.02;22 - 39岁:HR = 1.4,P = 0.06)。CCC/COG机构中儿童和15至21岁患者的结果相当(HR = 1.3,P = 0.4),但22至39岁的患者结果较差(HR = 1.7,P = 0.05)。就诊情况:15至21岁的患者比儿童使用CCC/COG机构的可能性更小(P < 0.001)。在22至39岁的患者中,公立医疗/未参保者(ALL:P = 0.004;AML:P < 0.001)、非裔美国人/西班牙裔(ALL:P = 0.03)以及30至39岁的患者(ALL:P = 0.03)使用CCC/COG机构的可能性更小。CCC/COG机构的治疗可缓解ALL和AML患者AYA的低生存率。CCC/COG机构治疗的障碍包括公立医疗/未参保者以及非裔美国人/西班牙裔种族/族裔。CCC/COG机构的治疗在一定程度上解释了ALL和AML患者AYA较差的治疗结果。关键的社会人口学因素是专科中心治疗的障碍。